BioSpace News Archive

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update.

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization, announced the company completed the expansion of its manufacturing space at its Milan Cell & Gene Center of Excellence production site.

Protagonist Therapeutics today announced it has received approximately $34.4 million in proceeds from the exercise of warrants to purchase 2.75 million shares of the Company’s Common Stock.

Diality Inc. today announced the closing of a $28 million investment round. The funding will be used to support Diality’s 510(k) filing and pre-commercialization activities through initial commercial launch targeting hospitals, skilled nursing facilities, and de novo clinics.

BrainsWay Ltd. today reported second quarter 2023 financial results and provided an operational update.

CalciMedica Inc. today announced that its ongoing CARPO trial, a Phase 2b trial evaluating Auxora™ for the treatment of acute pancreatitis (AP) with accompanying systemic inflammatory response syndrome (SIRS), was expanded to clinical research sites in India and that the first patient has been enrolled there.

Medicenna Therapeutics Corp. today announced a clinical update on the monotherapy dose escalation portion of the first-in-human, Phase 1/2 ABILITY Study in patients with advanced solid tumors, as its drug candidate MDNA11, a beta-only, long-acting IL-2 super-agonist, advances to the monotherapy dose expansion phase.

PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor agnostic therapies targeting p53, today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.

Elicio Therapeutics today announced the publication of preclinical data demonstrating its lymph node-targeting Amphiphile (AMP) adjuvant.

Nuvectis Pharma, Inc. today reported its financial results for the second quarter 2023 and provided an update on recent pipeline progress.